Does the media refer more to QURE or CADL?

In the previous week, Candel Therapeutics had 2 more articles in the media than uniQure. MarketBeat recorded 3 mentions for Candel Therapeutics and 1 mentions for uniQure. uniQure's average media sentiment score of 0.72 beat Candel Therapeutics' score of 0.45 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CADL or IMNM more profitable?

Immunome's return on equity of -51.15% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Immunome N/A -51.15% -47.32%

Does the media prefer CADL or IMNM?

In the previous week, Candel Therapeutics had 2 more articles in the media than Immunome. MarketBeat recorded 3 mentions for Candel Therapeutics and 1 mentions for Immunome. Immunome's average media sentiment score of 0.72 beat Candel Therapeutics' score of 0.45 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunome 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CADL or KLRA?

Candel Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A Kailera Therapeutics N/A N/A N/A -$3.65 thousand N/A

Is CADL or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Kailera Therapeutics N/A N/A N/A

Does the media prefer CADL or KLRA?

In the previous week, Candel Therapeutics and Candel Therapeutics both had 3 articles in the media. Candel Therapeutics' average media sentiment score of 0.45 beat Kailera Therapeutics' score of 0.24 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, CADL or KOD?

Kodiak Sciences is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A

Is CADL or KOD more profitable?

Candel Therapeutics' return on equity of -60.42% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Kodiak Sciences N/A -253.85% -81.48%

Does the media favor CADL or KOD?

In the previous week, Candel Therapeutics had 1 more articles in the media than Kodiak Sciences. MarketBeat recorded 3 mentions for Candel Therapeutics and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.84 beat Candel Therapeutics' score of 0.45 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, TRVI or CADL?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A

Is TRVI or CADL more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -24.53% -23.37% Candel Therapeutics N/A -60.42% -41.33%

Does the media refer more to TRVI or CADL?

In the previous week, Trevi Therapeutics had 9 more articles in the media than Candel Therapeutics. MarketBeat recorded 12 mentions for Trevi Therapeutics and 3 mentions for Candel Therapeutics. Trevi Therapeutics' average media sentiment score of 0.89 beat Candel Therapeutics' score of 0.45 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Candel Therapeutics (CADL) Competitors

$9.57 -0.61 (-5.99%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$9.75 +0.18 (+1.88%)

As of 07/20/2026 07:56 PM Eastern

Compare

CADL vs. QURE, IMNM, KLRA, KOD, and TRVI

Should you buy Candel Therapeutics stock or one of its competitors? MarketBeat compares Candel Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Candel Therapeutics include uniQure (QURE), Immunome (IMNM), Kailera Therapeutics (KLRA), Kodiak Sciences (KOD), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry.

How does Candel Therapeutics compare to uniQure?

uniQure (NASDAQ:QURE) and Candel Therapeutics (NASDAQ:CADL) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Candel Therapeutics has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	155.52	-$198.97M	-$3.48	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

78.8% of uniQure shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

uniQure presently has a consensus price target of $64.17, suggesting a potential upside of 61.63%. Candel Therapeutics has a consensus price target of $18.57, suggesting a potential upside of 94.06%. Given Candel Therapeutics' higher probable upside, analysts clearly believe Candel Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

uniQure has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.52, indicating that its stock price is 152% less volatile than the broader market.

In the previous week, Candel Therapeutics had 2 more articles in the media than uniQure. MarketBeat recorded 3 mentions for Candel Therapeutics and 1 mentions for uniQure. uniQure's average media sentiment score of 0.72 beat Candel Therapeutics' score of 0.45 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Candel Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Candel Therapeutics' return on equity of -60.42% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Candel Therapeutics	N/A	-60.42%	-41.33%

Summary

Candel Therapeutics beats uniQure on 8 of the 15 factors compared between the two stocks.

How does Candel Therapeutics compare to Immunome?

Candel Therapeutics (NASDAQ:CADL) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Candel Therapeutics has higher earnings, but lower revenue than Immunome. Candel Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Immunome	$6.94M	361.62	-$212.39M	-$2.38	N/A

In the previous week, Candel Therapeutics had 2 more articles in the media than Immunome. MarketBeat recorded 3 mentions for Candel Therapeutics and 1 mentions for Immunome. Immunome's average media sentiment score of 0.72 beat Candel Therapeutics' score of 0.45 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunome	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunome's return on equity of -51.15% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Immunome	N/A	-51.15%	-47.32%

Candel Therapeutics currently has a consensus target price of $18.57, indicating a potential upside of 94.06%. Immunome has a consensus target price of $33.17, indicating a potential upside of 49.67%. Given Candel Therapeutics' higher probable upside, equities research analysts plainly believe Candel Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Immunome	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Candel Therapeutics has a beta of -0.52, suggesting that its share price is 152% less volatile than the broader market. Comparatively, Immunome has a beta of 2.07, suggesting that its share price is 107% more volatile than the broader market.

Summary

Immunome beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Candel Therapeutics compare to Kailera Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Candel Therapeutics currently has a consensus price target of $18.57, indicating a potential upside of 94.06%. Kailera Therapeutics has a consensus price target of $42.75, indicating a potential upside of 138.69%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Candel Therapeutics and Candel Therapeutics both had 3 articles in the media. Candel Therapeutics' average media sentiment score of 0.45 beat Kailera Therapeutics' score of 0.24 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Candel Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A

Kailera Therapeutics' return on equity of 0.00% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Kailera Therapeutics	N/A	N/A	N/A

13.9% of Candel Therapeutics shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Kailera Therapeutics beats Candel Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Candel Therapeutics compare to Kodiak Sciences?

Candel Therapeutics (NASDAQ:CADL) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

In the previous week, Candel Therapeutics had 1 more articles in the media than Kodiak Sciences. MarketBeat recorded 3 mentions for Candel Therapeutics and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.84 beat Candel Therapeutics' score of 0.45 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kodiak Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Candel Therapeutics' return on equity of -60.42% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Kodiak Sciences	N/A	-253.85%	-81.48%

Candel Therapeutics presently has a consensus target price of $18.57, suggesting a potential upside of 94.06%. Kodiak Sciences has a consensus target price of $42.14, suggesting a potential upside of 3.11%. Given Candel Therapeutics' higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Kodiak Sciences is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Candel Therapeutics has a beta of -0.52, indicating that its share price is 152% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market.

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Candel Therapeutics beats Kodiak Sciences on 8 of the 13 factors compared between the two stocks.

How does Candel Therapeutics compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Candel Therapeutics (NASDAQ:CADL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Trevi Therapeutics presently has a consensus price target of $24.91, indicating a potential upside of 48.53%. Candel Therapeutics has a consensus price target of $18.57, indicating a potential upside of 94.06%. Given Candel Therapeutics' higher possible upside, analysts plainly believe Candel Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Trevi Therapeutics had 9 more articles in the media than Candel Therapeutics. MarketBeat recorded 12 mentions for Trevi Therapeutics and 3 mentions for Candel Therapeutics. Trevi Therapeutics' average media sentiment score of 0.89 beat Candel Therapeutics' score of 0.45 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Trevi Therapeutics' return on equity of -24.53% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Candel Therapeutics	N/A	-60.42%	-41.33%

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Trevi Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.Comparatively, Candel Therapeutics has a beta of -0.52, meaning that its share price is 152% less volatile than the broader market.

Summary

Trevi Therapeutics beats Candel Therapeutics on 11 of the 14 factors compared between the two stocks.

Get Candel Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CADL vs. The Competition

Export

Metric	Candel Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$745.89M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-9.77	20.49	27.10	23.94
Price / Sales	N/A	300.39	517.51	91.95
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	10.07	7.92	10.66	6.14
Net Income	-$38.18M	$23.81M	$3.60B	$331.74M
7 Day Performance	-0.73%	-1.27%	-1.51%	-1.72%
1 Month Performance	15.16%	2.56%	1.11%	-1.44%
1 Year Performance	41.99%	42.49%	23.77%	16.97%

Candel Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CADL Candel Therapeutics	2.6201 of 5 stars	$9.57 -6.0%	$18.57 +94.1%	+42.0%	$745.89M	N/A	N/A	60	Analyst Forecast
QURE uniQure	3.7281 of 5 stars	$41.10 -3.6%	$64.17 +56.1%	+164.8%	$2.69B	$16.10M	N/A	500
IMNM Immunome	3.1484 of 5 stars	$22.80 -2.4%	$33.17 +45.5%	+109.5%	$2.64B	$6.94M	N/A	40
KLRA Kailera Therapeutics	3.9823 of 5 stars	$19.97 -3.4%	$42.75 +114.1%	N/A	$2.59B	N/A	N/A	145
KOD Kodiak Sciences	0.9639 of 5 stars	$41.10 -0.5%	$42.14 +2.5%	+640.4%	$2.59B	N/A	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CADL) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Candel Therapeutics (CADL) Competitors

CADL vs. QURE, IMNM, KLRA, KOD, and TRVI

How does Candel Therapeutics compare to uniQure?

Summary

How does Candel Therapeutics compare to Immunome?

Summary

How does Candel Therapeutics compare to Kailera Therapeutics?

Summary

How does Candel Therapeutics compare to Kodiak Sciences?

Summary

How does Candel Therapeutics compare to Trevi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Candel Therapeutics (CADL) Competitors

CADL vs. QURE, IMNM, KLRA, KOD, and TRVI

How does Candel Therapeutics compare to uniQure?

Which has preferable earnings and valuation, QURE or CADL?

Do insiders & institutionals hold more shares of QURE or CADL?

Do analysts rate QURE or CADL?

Which has more risk & volatility, QURE or CADL?

Does the media refer more to QURE or CADL?

Is QURE or CADL more profitable?

Summary

How does Candel Therapeutics compare to Immunome?

Which has stronger earnings and valuation, CADL or IMNM?

Does the media prefer CADL or IMNM?

Is CADL or IMNM more profitable?

Do analysts rate CADL or IMNM?

Do insiders and institutionals have more ownership in CADL or IMNM?

Which has more risk and volatility, CADL or IMNM?

Summary

How does Candel Therapeutics compare to Kailera Therapeutics?

Do analysts prefer CADL or KLRA?

Does the media prefer CADL or KLRA?

Which has higher valuation and earnings, CADL or KLRA?

Is CADL or KLRA more profitable?

Do institutionals & insiders believe in CADL or KLRA?

Summary

How does Candel Therapeutics compare to Kodiak Sciences?

Does the media favor CADL or KOD?

Is CADL or KOD more profitable?

Do analysts prefer CADL or KOD?

Which has stronger valuation and earnings, CADL or KOD?

Which has more volatility and risk, CADL or KOD?

Do institutionals and insiders have more ownership in CADL or KOD?

Summary

How does Candel Therapeutics compare to Trevi Therapeutics?

Do analysts recommend TRVI or CADL?

Does the media refer more to TRVI or CADL?

Do institutionals and insiders believe in TRVI or CADL?

Is TRVI or CADL more profitable?

Which has better earnings & valuation, TRVI or CADL?

Which has more volatility & risk, TRVI or CADL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools